TORSEMIDE tablet

Country: Bandaríkin

Tungumál: enska

Heimild: NLM (National Library of Medicine)

Virkt innihaldsefni:

TORSEMIDE (UNII: W31X2H97FB) (TORSEMIDE - UNII:W31X2H97FB)

Fáanlegur frá:

Direct_Rx

Stjórnsýsluleið:

ORAL

Gerð lyfseðils:

PRESCRIPTION DRUG

Ábendingar:

1.1 Edema Torsemide tablets are indicated for the treatment of edema associated with heart failure, renal disease or hepatic disease. 1.2 Hypertension Torsemide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with torsemide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guideli

Vörulýsing:

Torsemide tablets USP, 5 mg are white to off white, oval shaped, scored tablets, debossed with ‘56’ on scored side and ‘H’ on the opposite side. They are supplied as follows: 31722-529-01, bottle of 100 31722-529-05, bottle of 500 Torsemide tablets USP, 10 mg are white to off white, oval shaped, scored tablets, debossed with ‘57’ on scored side and ‘H’ on the opposite side. They are supplied as follows: 31722-530-01, bottle of 100 31722-530-05, bottle of 500 Torsemide tablets USP, 20 mg are white to off white, oval shaped, scored tablets, debossed with ‘59’ on scored side and ‘H’ on the opposite side. They are supplied as follows: 31722-531-01, bottle of 100 31722-531-05, bottle of 500 Torsemide tablets USP, 100 mg are white to off white, oval shaped, scored tablets, debossed with ‘60’ on scored side and ‘H’ on the opposite side. They are supplied as follows: 31722-532-01, bottle of 100 31722-532-05, bottle of 500 Storage Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]

Leyfisstaða:

Abbreviated New Drug Application

Vara einkenni

TORSEMIDE- TORSEMIDE TABLET
DIRECT_RX
----------
TORSEMIDE
1.1 Edema
Torsemide tablets are indicated for the treatment of edema associated
with heart failure,
renal disease or hepatic disease.
1.2 Hypertension
Torsemide tablets are indicated for the treatment of hypertension, to
lower blood
pressure. Lowering blood pressure reduces the risk of fatal and
nonfatal cardiovascular
events, primarily strokes and myocardial infarctions. These benefits
have been seen in
controlled trials of antihypertensive drugs from a wide variety of
pharmacologic classes
including the class to which this drug principally belongs. There are
no controlled trials
demonstrating risk reduction with torsemide tablets.
Control of high blood pressure should be part of comprehensive
cardiovascular risk
management, including, as appropriate, lipid control, diabetes
management,
antithrombotic therapy, smoking cessation, exercise, and limited
sodium intake. Many
patients will require more than one drug to achieve blood pressure
goals. For specific
advice on goals and management, see published guidelines, such as
those of the
National High Blood Pressure Education Program’s Joint National
Committee on
Prevention, Detection, Evaluation, and Treatment of High Blood
Pressure (JNC).
Numerous antihypertensive drugs, from a variety of pharmacologic
classes and with
different mechanisms of action, have been shown in randomized
controlled trials to
reduce cardiovascular morbidity and mortality, and it can be concluded
that it is blood
pressure reduction, and not some other pharmacologic property of the
drugs, that is
largely responsible for those benefits. The largest and most
consistent cardiovascular
outcome benefit has been a reduction in the risk of stroke, but
reductions in myocardial
infarction and cardiovascular mortality also have been seen regularly.
Elevated systolic or diastolic pressure causes increased
cardiovascular risk, and the
absolute risk increase per mmHg is greater at higher blood pressures,
so that even
modest reductions of severe